The subject has experienced any of the following* Clinically-significant gastrointestinal bleeding within 3 months before the first dose of study treatment; the participant must be maintained on a prophylactic regimen for management of an upper gastrointestinal (GI) bleeding event with no evidence of recurrence and/or endoscopic confirmation of resolution of the source of a lower GI bleed* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatmentXx_NEWLINE_xXThe participant has experienced any of the following:* Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatmentXx_NEWLINE_xXThe subject has experienced any of the following:* Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatmentXx_NEWLINE_xXThe subject has experienced any of the following:* Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatmentXx_NEWLINE_xXThe subject has experienced any of the following:* Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment* Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the first dose of study treatment* Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatmentXx_NEWLINE_xXPatients must not have had hemoptysis of >= 0.5 teaspoon (2.5 ml) of red blood within 3 months prior registrationXx_NEWLINE_xX